EXOR N.V. (“Exor” or the “Company”) announces that all the resolutions proposed by the Board of Directors to the Annual General Meeting of Shareholders (the “AGM”) held virtually today were approved.

Exor N.V. (“Exor”), a leading diversified holding company controlled by the Agnelli family, has signed an agreement to acquire a 45% shareholding in Lifenet S.r.l. (“Lifenet Healthcare” or “the Company”), an Italian company active in the healthcare sector, particularly in the management of hospitals and outpatient clinics. The transaction, which will be executed principally via a capital increase reserved for Exor and the concurrent acquisition of shares owned by Invin S.r.l., the company that controls Lifenet, entails a total investment by Exor of €67 million.

Exor announces the launch of an Italy-focused seed initiative to support the country’s most promising entrepreneurs building the next generation of great companies. Exor Seeds (early stage venture arm of Exor) will invest in pre-seed and seed stage startups offering a €150K investment with an efficient diligence process, founder-friendly terms, and no board seat.

The Exor Board of Directors’ meeting, chaired by John Elkann, approved today the 2021 Annual Report, which will be submitted for adoption to the Annual General Meeting of Shareholders on 24 May 2022.

EXOR N.V. (“the Company”) announces today that it will launch a share buyback program (“the Program”). The Company expects that the Program will involve the repurchase from time to time of up to €500mn of ordinary shares by 2024, in line with the disclosure made at the 2021 Investor Day.

Exor N.V. (“Exor” or “the Company”) announces that it has today settled with the Italian Tax Authorities (“Agenzia delle Entrate”) on a complex tax issue, specifically in respect of the Exit Tax.

EXOR N.V. announced today the following Corporate Calendar for 2022:

•   24 March 2022: Board of Directors Meeting for the approval of the Company’s 2021 Annual Report